Yung Soon Yim
Pediatric Hematology-Oncology · Sacramento, CANPI 1083701007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $591 and has fallen 87.7% since, to $73 in 2025.
Across 129 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$497
- Novartis$436
- Servier Pharmaceuticals LLC$291
- AstraZeneca$280
- Sobi, Inc$245
- Y-mabs Therapeutics, Inc.$146
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,74194%
- Education$1706%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $497 |
| Novartis | 21 | $436 |
| Servier Pharmaceuticals LLC | 15 | $291 |
| AstraZeneca(2 entities) | 13 | $280 |
| Sobi, Inc | 12 | $245 |
| Y-mabs Therapeutics, Inc. | 5 | $146 |
| BTG International Inc. | 6 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Pfizer | 3 | $80 |
| Astellas Pharma US Inc | 2 | $72 |
| Bio Products Laboratory USA, Inc. | 3 | $65 |
| USWM, LLC | 2 | $64 |
| Jazz Pharmaceuticals Inc. | 2 | $61 |
| Bayer | 2 | $49 |
| Emmaus Medical, Inc. | 3 | $49 |
| Apo-pharma USA, Inc. | 2 | $44 |
| Genentech USA, Inc. | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $41 |
| Biomarin Pharmaceutical Inc. | 1 | $32 |
| Krystal Biotech Inc | 1 | $31 |
| Chiesi USA, Inc. | 1 | $23 |
| Global Blood Therapeutics, Inc. | 1 | $23 |
| CSL Behring | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| United Therapeutics Corporation | 1 | $14 |
| Fortovia Therapeutics, Inc. | 1 | $11 |
How this compares
$2,911 in reported general payments places this provider in the 65th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Sacramento
- Arun PanigrahiSacramento$103K
- Anjali PawarSacramento$28K
- Jonathan DucoreSacramento$23K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.